CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1–Infected Children Receiving Highly Active Antiretroviral Therapy.
In: JAIDS: Journal of Acquired Immune Deficiency Syndromes, Jg. 54 (2010-07-01), Heft 3, S. 285-289
Online
academicJournal
Zugriff:
The article presents a study which examines the effect of P-glycoprotein (ABCB1) genetic variants and cytochrome P450 (CYP) on nelfinavir pharmacokinetics and virologic response to highly active antiretroviral therapy (HAART) in HIV-1-infected children. Researchers perform genomic DNA assay among HIV-1-infected children using real-time polymerase chain reaction (PCR). Results show that nelfinavir pharmacokinetics and response to HAART in children are changed by CYP2C19 genotypes.
Titel: |
CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1–Infected Children Receiving Highly Active Antiretroviral Therapy.
|
---|---|
Autor/in / Beteiligte Person: | Saitoh, Akihiko ; Capparelli, Edmund ; Aweeka, Francesca ; Sarles, Elizabeth ; Singh, Kumud K. ; Kovacs, Andrea ; Burchett, Sandra K. ; Wiznia, Andrew ; Nachman, Sharon ; Fenton, Terence ; Spector, Stephen A. |
Link: | |
Zeitschrift: | JAIDS: Journal of Acquired Immune Deficiency Syndromes, Jg. 54 (2010-07-01), Heft 3, S. 285-289 |
Veröffentlichung: | 2010 |
Medientyp: | academicJournal |
ISSN: | 1525-4135 (print) |
DOI: | 10.1097/QAI.0b013e3181bf648a |
Schlagwort: |
|
Sonstiges: |
|